Does atenolol cause hair loss? This is a question many patients prescribed this common beta-blocker ask, particularly after noticing increased shedding or thinning. Atenolol is widely used in the UK for hypertension, angina, and cardiac arrhythmias, and whilst it is generally well tolerated, alopecia is listed as a rare side effect in UK Summaries of Product Characteristics. Understanding how common this side effect is, why it may occur, and what steps to take if you notice hair changes can help you have an informed conversation with your GP or prescribing clinician.

Can Atenolol Cause Hair Loss?

Yes — alopecia is listed as a rare side effect of atenolol in UK SmPCs, estimated to affect between 1 in 1,000 and 1 in 10,000 patients. Never stop atenolol abruptly; always consult your GP first.

Experiencing these side effects? Our pharmacists can help you navigate them →

Atenolol is a selective beta-1 adrenoceptor blocker widely prescribed in the UK for conditions including hypertension, angina, and certain cardiac arrhythmias.^[1][2] It works by blocking the effects of adrenaline on the heart, reducing heart rate and blood pressure. Like many long-term medications, atenolol carries a range of potential side effects, and hair loss — known medically as alopecia — is one that patients sometimes report.

According to UK Summaries of Product Characteristics (SmPCs) for atenolol products available on the Electronic Medicines Compendium (emc), alopecia is listed as a rare side effect. Using standard EMA/MHRA frequency definitions, 'rare' means it is estimated to affect between 1 in 10,000 and 1 in 1,000 people taking the medication.^[2][3] This means it has been reported in clinical use but does not affect the great majority of patients. Hair loss associated with atenolol often improves after stopping the drug, if it is confirmed as the cause, though you should always seek medical advice before making any changes.

Patients who notice hair thinning whilst taking atenolol should not stop the medication abruptly without medical advice. Sudden withdrawal of beta-blockers can cause rebound effects — including a rapid increase in heart rate and blood pressure — which may be dangerous, particularly in those with underlying cardiac conditions.^[9] Always consult your GP or prescribing clinician before making any changes to your medication. The BNF advises gradual withdrawal of beta-blockers where possible.

How Beta-Blockers May Affect Hair Growth

Beta-blockers may trigger telogen effluvium by disrupting adrenergic signalling in hair follicles or reducing scalp blood flow, though no single confirmed mechanism exists. Hair shedding typically begins two to three months after the triggering event.

To understand why atenolol might contribute to hair loss, it helps to consider the biology of hair growth. Hair follicles cycle through phases: anagen (active growth), catagen (transition), and telogen (resting/shedding). Disruptions to this cycle — whether hormonal, nutritional, or drug-induced — can push a larger proportion of follicles into the telogen phase simultaneously, resulting in diffuse shedding known as telogen effluvium. Importantly, telogen effluvium typically begins two to three months after the triggering event, such as starting or increasing the dose of a new medication.^[6][8] This latency period is useful when trying to establish whether atenolol is the likely cause.

Not sure if this is normal? Chat with one of our pharmacists →

The precise mechanism by which beta-blockers may contribute to hair loss in susceptible individuals is not fully established. Adrenergic receptors are present in hair follicle tissue, and it has been proposed — though not definitively confirmed in clinical studies — that blocking these receptors may alter the local signalling environment supporting normal follicle activity. Some researchers have also suggested that beta-blockade could theoretically reduce peripheral blood flow to the scalp, potentially affecting nutrient and oxygen delivery to follicles; however, this remains a theoretical hypothesis without robust clinical evidence.

Beta-blockers may also influence hormonal and stress-response pathways that interact with hair follicle biology. The physiological adjustment to a new cardiovascular medication may itself act as a trigger for a temporary episode of telogen effluvium, making it difficult to attribute hair loss solely to the pharmacological action of atenolol. There is no single confirmed pathway that fully explains the association, and mechanistic explanations should be regarded as provisional. For further information on telogen effluvium, the British Association of Dermatologists (BAD) provides patient information on this condition.^[8]

How Common Is Hair Loss With Atenolol?

Hair loss is classified as rare with atenolol, meaning it affects fewer than 1 in 1,000 patients. The pattern is typically diffuse thinning consistent with telogen effluvium, not patterned baldness.

Using standard EMA/MHRA frequency definitions:

• Very common: affects more than 1 in 10 people

• Common: affects between 1 in 10 and 1 in 100 people

• Uncommon: affects between 1 in 100 and 1 in 1,000 people

• Rare: affects between 1 in 1,000 and 1 in 10,000 people

• Very rare: affects fewer than 1 in 10,000 people

Alopecia is classified as a rare side effect in UK atenolol SmPCs (available on the emc for products such as those manufactured by Accord, Teva, and the originator Tenormin).^[1][2] The majority of patients taking atenolol do not experience any noticeable hair thinning.

Hair loss associated with beta-blockers tends to be diffuse rather than patterned — typically presenting as generalised thinning across the scalp rather than in specific areas. This pattern is characteristic of telogen effluvium and is distinct from androgenetic alopecia (male or female pattern baldness), which follows a more predictable distribution. Diffuse hair loss can be distressing but is usually not permanent when the causative agent is identified and addressed.

It is also important to consider that many patients prescribed atenolol have underlying health conditions — such as hypertension or cardiovascular disease — that may themselves be associated with hair changes. Stress, poor nutrition, thyroid dysfunction, and iron deficiency are all common causes of hair loss in the general population and should be excluded before attributing the symptom to atenolol alone. A thorough clinical assessment is therefore essential, including:

• Full blood count (FBC) — to check for anaemia

• Serum ferritin — iron deficiency is a frequent and often overlooked cause of hair loss, particularly in women

• Thyroid function tests (TSH, free T4) — both hypothyroidism and hyperthyroidism can cause hair thinning

• Vitamin B12 and vitamin D — only if the clinical history or examination suggests a possible deficiency

• Medication review — to identify any other drugs that may contribute

• Assessment of timeline — did hair loss begin approximately two to three months after starting or increasing the dose of atenolol?

NICE Clinical Knowledge Summaries (CKS) on alopecia and the NHS hair loss page provide further guidance on the assessment of hair loss in primary care.^[6][7]

What to Do If You Notice Hair Thinning on Atenolol

Speak to your GP rather than stopping atenolol independently; they will take a detailed history and arrange blood tests to exclude common treatable causes such as iron deficiency and thyroid dysfunction.

If you begin to notice increased hair shedding or visible thinning whilst taking atenolol, the first step is to speak to your GP or prescribing clinician rather than stopping the medication independently. Your doctor will want to take a detailed history, including when the hair loss started in relation to when you began atenolol (bearing in mind the typical two-to-three-month latency of telogen effluvium), the pattern and severity of shedding, and any other symptoms you may have noticed.

Your GP is likely to arrange blood tests to rule out other common and treatable causes of hair loss. In line with UK practice, first-line investigations typically include:

• Full blood count (FBC) — to check for anaemia

• Serum ferritin — iron deficiency is a frequent and often overlooked cause of hair loss, particularly in women

• Thyroid function tests (TSH, free T4) — both hypothyroidism and hyperthyroidism can cause hair thinning

• Vitamin B12 and vitamin D — considered if the clinical history or examination suggests a possible deficiency

If investigations are normal and the timeline strongly suggests atenolol as the likely cause, your doctor may consider whether a dose adjustment or switch to an alternative medication is appropriate. This decision will always be balanced against the clinical need for the medication — for example, in a patient with well-controlled hypertension or a history of myocardial infarction, the cardiovascular benefits of continuing beta-blocker therapy are significant.

Seek prompt medical advice if hair loss is accompanied by other symptoms such as unexplained weight changes, fatigue, palpitations, or skin changes, as these may indicate an underlying systemic condition requiring investigation in its own right.

You should also be referred to a dermatologist or appropriate specialist if any of the following apply:

• Signs of scarring or inflammation on the scalp

• Rapid or patchy hair loss (which may suggest alopecia areata or another condition)

• Diagnostic uncertainty after initial assessment

• Hair loss that is severe or persistent despite addressing identifiable causes

NICE CKS on alopecia provides clear guidance on referral thresholds and management in primary care.^[6]

Alternative Medications and Managing Side Effects

If atenolol is confirmed as the cause, your doctor may consider switching to a non-beta-blocker, such as an ACE inhibitor or calcium channel blocker, depending on your indication. Any change must be made gradually under medical supervision.

If atenolol is confirmed as the likely cause of hair loss and the side effect is significantly affecting your quality of life, your GP or cardiologist may consider switching to an alternative agent. It is important to understand that hair loss has been reported with other beta-blockers as well — including propranolol, bisoprolol, and metoprolol — so switching within the same drug class may not necessarily resolve the problem. However, individual responses to different beta-blockers can vary, and some patients tolerate one agent better than another.

It is also worth noting that, in line with NICE guideline NG136 (Hypertension in adults), beta-blockers are not recommended as a routine first-line treatment for uncomplicated hypertension. First-line options for most patients include ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, or thiazide-like diuretics, depending on age, ethnicity, and comorbidities. These drug classes are not typically associated with drug-induced alopecia and may represent suitable alternatives for patients whose atenolol was prescribed primarily for blood pressure control.

However, the choice of alternative medication is indication-specific. For patients taking atenolol for angina, rate control in atrial fibrillation, or following myocardial infarction, the decision to switch requires specialist input, as alternative agents (such as rate-limiting calcium channel blockers for some indications) may be appropriate in selected cases. Any change in therapy should be made gradually and under medical supervision, with appropriate monitoring to ensure continued clinical control. Do not stop atenolol abruptly — always follow your doctor's advice on how to reduce or switch the medication safely.

If telogen effluvium is confirmed as the cause of hair loss, reassurance is often the most important intervention — the condition is usually self-limiting once the trigger is removed or stabilised. Ensuring adequate nutrition, particularly sufficient protein, iron, and vitamins, supports healthy hair regrowth. Dermatology referral may be appropriate if hair loss is severe, persistent, or diagnostically uncertain.

Finally, patients are encouraged to report suspected side effects from atenolol or any other medication using the MHRA Yellow Card scheme, available at yellowcard.mhra.gov.uk. Reporting helps build the evidence base for drug safety and contributes to better guidance for future patients.

Frequently Asked Questions